Article
[GIST refractory to imatinib treatment].
Gan to kagaku ryoho. Cancer & chemotherapy - 1 May 2011
Onozawa Yusuke, Terashima Masanori
Abstract excerpt
After the introduction of imatinib, the outcome for patients with advanced gastro-intestinal stromal tumor (GIST) was vastly improved. However, resistance to imatinib has become a new problem. The cause of resistance to imatinib is the low sensitivity of gene mutations in the KIT gene or PDGFRα, or an acquisition of additional mutations, and a low plasma level of imatinib. Sunitinib is the first drug that showed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.